Classis Completes Acquisition of Brazil's JL Health

Classis Co., Ltd. (CEO Choi Yoon-seok) announced on the 5th that it has completed the acquisition of Brazilian medical device distribution group JL Health and appointed Andrea Lima, former head of Allergan Aesthetics' Brazilian business, as the new CEO, thereby launching a direct management system in Central and South America.

JL Health's enterprise value is estimated at approximately KRW 100 billion, and Classis has acquired a 77.5% stake in JL Health, which wholly owns MedSystems. Classis will also acquire the full distribution subsidiaries of JL Health in Colombia and Argentina, establishing a direct distribution and sales network in key Central and South American markets. Through this acquisition, Classis plans to secure over 15,000 customer touchpoints and actively pursue market expansion for existing and new products.

This acquisition of a Brazilian distributor is considered a significant milestone in Classis's expansion strategy in Central and South America. Building on the market dominance and brand credibility of the Ultraformer (known in Korea as Shrink) in Brazil, the company plans to secure market access for next-generation equipment like the Volnumer and new QuadSay products.

“Together with Classis, we will provide innovative medical device technologies and clinical training in Brazil, expand our global customer service, and grow our Brazilian operations into a strategic hub,” said CEO Andrea Lima. “This acquisition will serve as a catalyst for rapid investment and aggressive business expansion.”

Choi Yoon-seok, CEO of Classis, stated, "Brazil is a market with high growth potential, and the acquisition of MedSystems is expected to improve sales and profitability. In the medium to long term, this will have a positive impact on profitability across the entire Latin American market." He added, "The Brazilian market will provide strategic momentum for our global expansion, including Volneumer's entry into the Chinese market and Ultraformer's entry into the US market."

• See more related articles